Vertex Pharmaceuticals Incorporated (vrtx)
VRTX Earnings
Public earnings and growth snapshot for Vertex Pharmaceuticals Incorporated. Full earnings calendars, surprises, and multi-year history are available in Vest Terminal.
| Earnings growth (YoY) | 8.0% |
| Revenue growth (YoY) | 12.5% |
| Trailing P/E | 30.04 |
| Forward P/E | 25.70 |
| Last price | $516.34 |
| Market cap | $130.87B |
Start Free — open VRTX in Vest Terminal
Access live data, filings, ownership, and analysis for Vertex Pharmaceuticals Incorporated.
Vertex Pharmaceuticals Incorporated FAQ
What does Vertex Pharmaceuticals Incorporated (VRTX) do?
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell di…
What is VRTX's P/E ratio?
Vertex Pharmaceuticals Incorporated has a trailing P/E of 30.04× based on publicly available market data.
Does VRTX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is VRTX in?
Vertex Pharmaceuticals Incorporated is classified in Healthcare (Biotechnology) on NMS.
What is VRTX's market capitalization?
Approximate market cap: $130.87B.
What are the main risks for VRTX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VRTX?
Potential positives include revenue growth of 12.5% year-over-year, earnings growth of 8.0% year-over-year.
Where can I get analyst estimates for VRTX?
Public analyst price targets and consensus for Vertex Pharmaceuticals Incorporated are on the free /stocks/vrtx/estimates page. Deeper estimate history and models are available in Vest Terminal.